Steroid Utilization for Pediatric Ventricular Assist Device-Associated Inflammation and Association With Outcomes
Retrospective cohort published in ASAIO Journal (2025)
Abstract
The impact of methylprednisolone (MP) on ventricular assist device (VAD)-associated inflammation in children and its association with outcomes remains unclear. We report this single-center retrospective study of children less than 21 years old supported with a VAD from February 2018 to December 2022. Methylprednisolone utilization, serial laboratory markers of hemolysis, inflammation, anticoagulation, and VAD adverse outcomes were analyzed. Sixty-eight patients (47% male, median age 3.2 years, 54% pulsatile flow) were included. Thirty-three patients (49%) received MP during VAD support, starting at a median 9 days post-implant (interquartile range [IQR]: 7-14), and for a median of 4 days (IQR: 3-5). Post-MP, there was a significant reduction in c-reactive protein (CRP) (12.4-3.2 mg/dl, p < 0.001) and fibrinogen (592-325 mg/dl, p < 0.001). Patients receiving MP had a higher daily rate of decline of fibrinogen ( p = 0.024) and higher bivalirudin dose ( p = 0.013) in the 2nd week post-implant. Methylprednisolone utilization was associated with higher proportion of stroke ( p = 0.023), infection ( p = 0.010), and pump thrombosis ( p = 0.023). Methylprednisolone is used frequently during pediatric VAD support and reduces inflammatory markers. Infectious and thrombotic complications were more common in the cohort receiving MP, and larger studies are needed to investigate this further.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Sixty-eight pediatric VAD patients on bivalirudin showed that methylprednisolone administration reduced CRP and fibrinogen but was associated with higher rates of stroke, infection, and pump thrombosis, plus elevated bivalirudin dose requirements.
Por qué esto importa para la hirudoterapia
Este estudio retrospectivo unicéntrico de 68 pacientes pediátricos con dispositivo de asistencia ventricular (VAD) examinó la utilización de metilprednisolona (MP) para la inflamación asociada al dispositivo, encontrando que la MP (utilizada en el 49% de los pacientes) redujo significativamente la PCR y el fibrinógeno, pero se asoció con proporciones mayores de accidente cerebrovascular, infección y trombosis de la bomba. Los pacientes que recibieron MP también requirieron dosis más altas de bivalirudina en la segunda semana postimplante. El resumen menciona la bivalirudina solo como un anticoagulante con dosificación más alta en los receptores de MP y no proporciona detalles farmacológicos sobre ella; no hay mención de hirudina, saliva de sanguijuela, terapia con sanguijuelas ni del secretoma de la sanguijuela. El estudio se centra en el uso de corticosteroides para la inflamación, no en la anticoagulación, y no puede establecerse una relevancia defendible para el ámbito de ASH a partir del resumen.
Citación
Steroid Utilization for Pediatric Ventricular Assist Device-Associated Inflammation and Association With Outcomes.
Ankola AA et al. · ASAIO Journal, 2025
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 27, 2026 · Última actualización del sitio: 18 de junio de 2026